{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:31:07Z","timestamp":1648992667708},"reference-count":16,"publisher":"The Japan Geriatrics Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. geriat","Nippon Ronen Igakkai Zasshi","Nihon Ronen Igakkai Zasshi","Jpn J Geriat"],"published-print":{"date-parts":[[2003]]},"DOI":"10.3143\/geriatrics.40.520","type":"journal-article","created":{"date-parts":[[2007,3,28]],"date-time":"2007-03-28T05:49:35Z","timestamp":1175060975000},"page":"520-525","source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetic remission 10 years after the start of monotherapy with interferon α-2b in elderly chronic myelogenous leukemia"],"prefix":"10.3143","volume":"40","author":[{"given":"Masanori","family":"Umeda","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Katoh","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Arai","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Iijima","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Toho University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1704","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al.: Prognostic discrimination in “goodrisk” chronic granulocytic leukemia. Blood 1984; 63: 789-799.","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al.: Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.","DOI":"10.1182\/blood.V66.6.1326.1326"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J: Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol 1986; 64: 87-95.","DOI":"10.1111\/j.1365-2141.1986.tb07576.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J: Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.","DOI":"10.1182\/blood.V69.5.1280.1280"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ohnishi K, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, et al.: A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res 1998; 22: 779-786.","DOI":"10.1016\/S0145-2126(98)00082-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Eng J Med 1994; 330: 820-825.","DOI":"10.1056\/NEJM199403243301204"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Allan NC, Richards SM, Shepherd PCA: UK Medical Research Council randomized, multicenter trial of interferon-α n1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.","DOI":"10.1016\/S0140-6736(95)92596-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, et al.: Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642-647.","DOI":"10.1182\/blood.V72.2.642.642"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, et al.: Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group. Ann Hematol 1996; 72: 349-355.","DOI":"10.1007\/s002770050185"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.","DOI":"10.1093\/jnci\/90.11.850"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M: Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452-455.","DOI":"10.1016\/S0002-9343(97)89522-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, et al.: Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res 1998; 22: 881-886.","DOI":"10.1016\/S0145-2126(98)00064-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kloke O, Niederle N, Opalka B, Hawig I, Seeber S, Becher R: Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up. Eur J Haematol 1996; 56: 78-81.","DOI":"10.1111\/j.1600-0609.1996.tb00299.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kantarjian HM, Smith TL, O'Brien S, Heran M, Piece S, Talpaz M: Prolonged survival in chronic myelognous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122: 254-256.","DOI":"10.7326\/0003-4819-122-4-199502150-00003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al.: Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.","DOI":"10.1182\/blood-2002-02-0545"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, et al.: Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95: 881-887.","DOI":"10.1002\/cncr.10729"}],"container-title":["Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics"],"original-title":["\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u03b1-2b\u5358\u72ec\u6295\u4e0e\u306b\u3066\u6cbb\u7642\u958b\u59cb10\u5e74\u5f8c\u306b\u7d30\u80de\u907a\u4f1d\u5b66\u7684\u5bdb\u89e3\u3092\u5448\u3057\u3066\u3044\u308b\u9ad8\u9f62\u8005\u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5\u306e1\u4f8b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/geriatrics1964\/40\/5\/40_5_520\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T03:10:00Z","timestamp":1587438600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/geriatrics1964\/40\/5\/40_5_520\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.3143\/geriatrics.40.520","relation":{},"ISSN":["0300-9173"],"issn-type":[{"value":"0300-9173","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]}}}